Simplex Trading
ACRS icon

Simplex Trading’s Aclaris Therapeutics ACRS Stock Holding History

Simplex Trading’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$245K Buy
+65,200
New +$220K ﹤0.01% 4056
2025
Q1 		– Sell
-25,900
Closed -$64K – 8381
2024
Q4 		$64K Buy
25,900
+20,900
+418% +$52K ﹤0.01% 5602
2024
Q3 		$5K Buy
+5,000
New +$6.13K ﹤0.01% 7567
2024
Q1 		– Sell
-1,200
Closed -$1K – 8719
2023
Q4 		$1K Sell
1,200
-226,500
-99% -$691K ﹤0.01% 8417
2023
Q3 		$1.56M Buy
227,700
+92,800
+69% +$793K ﹤0.01% 2295
2023
Q2 		$1.4M Sell
134,900
-225,400
-63% -$2.04M ﹤0.01% 2267
2023
Q1 		$2.91M Buy
360,300
+360,100
+180,050% +$4.57M ﹤0.01% 1644
2022
Q4 		$3K Sell
200
-1,500
-88% -$24.1K ﹤0.01% 8325
2022
Q3 		$26K Sell
1,700
-3,900
-70% -$61.4K ﹤0.01% 7218
2022
Q2 		$78K Buy
5,600
+3,900
+229% +$54.7K ﹤0.01% 5894
2022
Q1 		$29K Sell
1,700
-400
-19% -$5.46K ﹤0.01% 7794
2021
Q4 		$30K Sell
2,100
-18,900
-90% -$286K ﹤0.01% 7886
2021
Q3 		$361K Hold
21,000
– – ﹤0.01% 4605
2021
Q2 		$368K Buy
21,000
+20,859
+14,794% +$474K ﹤0.01% 4635
2021
Q1 		$355K Buy
141
+136
+2,720% +$2.66K ﹤0.01% 3901
2020
Q4 		$3K Sell
5
-1
-17% -$4 ﹤0.01% 7847
2020
Q3 		$1K Buy
+6
New +$13 ﹤0.01% 7504
2020
Q2 		– Sell
-10
Closed -$1K – 7499
2020
Q1 		$1K Buy
+10
New +$14 ﹤0.01% 7303
2019
Q4 		– Sell
-23
Closed -$2K – 7191
2019
Q3 		$2K Sell
23
-23
-50% -$33 ﹤0.01% 6883
2019
Q2 		$10K Buy
46
+25
+119% +$136 ﹤0.01% 6088
2019
Q1 		$12K Buy
+21
New +$139 ﹤0.01% 6028

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Simplex Trading's ACRS Position: Q1 2026 in Review

Simplex Trading reduced its Aclaris Therapeutics (ACRS) stake by 33% in Q1 2026, selling an estimated $18.4K and leaving 11,216 shares worth $42.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6057.

Simplex Trading first reported a position in ACRS in Q4 2018 and has held it in 25 quarters since. The position peaked at $1.02M in Q1 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Simplex Trading held 11,216 shares of Aclaris Therapeutics worth $42.1K as of Q1 2026.
  • Simplex Trading sold 5,452 Aclaris Therapeutics shares in Q1 2026, an estimated $18.4K.
  • Aclaris Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #6057 holding.
  • Simplex Trading first reported a position in Aclaris Therapeutics in Q4 2018 and has held it in 25 quarters since.
  • Simplex Trading's Aclaris Therapeutics position peaked at $1.02M in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.